Safety evaluation of α‐lipoic acid supplementation: A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies

Federica Fogacci; Manfredi Rizzo; Christoffer Krogager; Cormac Kennedy; Coralie M.G. Georges; Tamara Knežević; Evangelos Liberopoulos; Alexandre Vallée; Pablo Pérez‐martínez; Eliane F.E. Wenstedt; Agnė Šatrauskienė; Michal Vrablík; Arrigo F.G. Cicero

doi:10.3390/antiox9101011

Safety evaluation of α‐lipoic acid supplementation: A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies

Federica Fogacci, Manfredi Rizzo, Christoffer Krogager, Cormac Kennedy, Coralie M.G. Georges, Tamara Knežević, Evangelos Liberopoulos, Alexandre Vallée, Pablo Pérez‐martínez, Eliane F.E. Wenstedt, Agnė Šatrauskienė, Michal Vrablík, Arrigo F.G. Cicero^*

^*Corresponding author for this work

Department of Clinical Medicine - Department of Endocrinology and Internal Medicine

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

46 Citations (Scopus)

Abstract

Alpha‐lipoic acid (ALA) is a natural short‐chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta‐analysis of the available randomized placebo‐controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA and 2294 assigned to placebo. A meta‐analysis of extracted data suggested that supplementation with ALA was not associated with an increased risk of any treatment‐emergent adverse event (all p > 0.05). ALA supplementation was safe, even in subsets of studies categorized according to smoking habit, cardiovascular disease, presence of diabetes, pregnancy status, neurological disorders, rheumatic affections, severe renal impairment, and status of children/adolescents at baseline.

Original language	English
Article number	1011
Journal	Antioxidants
Volume	9
Issue	10
Number of pages	33
ISSN	2076-3921
DOIs	https://doi.org/10.3390/antiox9101011
Publication status	Published - Oct 2020

Keywords

Dietary supplement
Meta‐analysis
Safety
Thioctic acid
α‐lipoic acid

Access to Document

10.3390/antiox9101011Licence: CC BY

Cite this

Fogacci, F., Rizzo, M., Krogager, C., Kennedy, C., Georges, C. M. G., Knežević, T., Liberopoulos, E., Vallée, A., Pérez‐martínez, P., Wenstedt, E. F. E., Šatrauskienė, A., Vrablík, M., & Cicero, A. F. G. (2020). Safety evaluation of α‐lipoic acid supplementation: A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies. Antioxidants, 9(10), Article 1011. https://doi.org/10.3390/antiox9101011

@article{55d5b25d5ad24d7d9822bdf6e625b65b,

title = "Safety evaluation of α‐lipoic acid supplementation: A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies",

abstract = "Alpha‐lipoic acid (ALA) is a natural short‐chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta‐analysis of the available randomized placebo‐controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA and 2294 assigned to placebo. A meta‐analysis of extracted data suggested that supplementation with ALA was not associated with an increased risk of any treatment‐emergent adverse event (all p > 0.05). ALA supplementation was safe, even in subsets of studies categorized according to smoking habit, cardiovascular disease, presence of diabetes, pregnancy status, neurological disorders, rheumatic affections, severe renal impairment, and status of children/adolescents at baseline.",

keywords = "Dietary supplement, Meta‐analysis, Safety, Thioctic acid, α‐lipoic acid",

author = "Federica Fogacci and Manfredi Rizzo and Christoffer Krogager and Cormac Kennedy and Georges, {Coralie M.G.} and Tamara Kne{\v z}evi{\'c} and Evangelos Liberopoulos and Alexandre Vall{\'e}e and Pablo P{\'e}rez‐mart{\'i}nez and Wenstedt, {Eliane F.E.} and Agnė {\v S}atrauskienė and Michal Vrabl{\'i}k and Cicero, {Arrigo F.G.}",

year = "2020",

month = oct,

doi = "10.3390/antiox9101011",

language = "English",

volume = "9",

journal = "Antioxidants",

issn = "2076-3921",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

Fogacci, F, Rizzo, M, Krogager, C, Kennedy, C, Georges, CMG, Knežević, T, Liberopoulos, E, Vallée, A, Pérez‐martínez, P, Wenstedt, EFE, Šatrauskienė, A, Vrablík, M & Cicero, AFG 2020, 'Safety evaluation of α‐lipoic acid supplementation: A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies', Antioxidants, vol. 9, no. 10, 1011. https://doi.org/10.3390/antiox9101011

Safety evaluation of α‐lipoic acid supplementation: A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies. / Fogacci, Federica; Rizzo, Manfredi; Krogager, Christoffer et al.
In: Antioxidants, Vol. 9, No. 10, 1011, 10.2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

TY - JOUR

T1 - Safety evaluation of α‐lipoic acid supplementation

T2 - A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies

AU - Fogacci, Federica

AU - Rizzo, Manfredi

AU - Krogager, Christoffer

AU - Kennedy, Cormac

AU - Georges, Coralie M.G.

AU - Knežević, Tamara

AU - Liberopoulos, Evangelos

AU - Vallée, Alexandre

AU - Pérez‐martínez, Pablo

AU - Wenstedt, Eliane F.E.

AU - Šatrauskienė, Agnė

AU - Vrablík, Michal

AU - Cicero, Arrigo F.G.

PY - 2020/10

Y1 - 2020/10

N2 - Alpha‐lipoic acid (ALA) is a natural short‐chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta‐analysis of the available randomized placebo‐controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA and 2294 assigned to placebo. A meta‐analysis of extracted data suggested that supplementation with ALA was not associated with an increased risk of any treatment‐emergent adverse event (all p > 0.05). ALA supplementation was safe, even in subsets of studies categorized according to smoking habit, cardiovascular disease, presence of diabetes, pregnancy status, neurological disorders, rheumatic affections, severe renal impairment, and status of children/adolescents at baseline.

AB - Alpha‐lipoic acid (ALA) is a natural short‐chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta‐analysis of the available randomized placebo‐controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA and 2294 assigned to placebo. A meta‐analysis of extracted data suggested that supplementation with ALA was not associated with an increased risk of any treatment‐emergent adverse event (all p > 0.05). ALA supplementation was safe, even in subsets of studies categorized according to smoking habit, cardiovascular disease, presence of diabetes, pregnancy status, neurological disorders, rheumatic affections, severe renal impairment, and status of children/adolescents at baseline.

KW - Dietary supplement

KW - Meta‐analysis

KW - Safety

KW - Thioctic acid

KW - α‐lipoic acid

UR - http://www.scopus.com/inward/record.url?scp=85093098714&partnerID=8YFLogxK

U2 - 10.3390/antiox9101011

DO - 10.3390/antiox9101011

M3 - Review

C2 - 33086555

AN - SCOPUS:85093098714

SN - 2076-3921

VL - 9

JO - Antioxidants

JF - Antioxidants

IS - 10

M1 - 1011

ER -

Safety evaluation of α‐lipoic acid supplementation: A systematic review and meta‐analysis of randomized placebo‐controlled clinical studies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this